Ariel Hurley - 15 Mar 2023 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Signature
/s/ Melissa Masse, Attorney-in-Fact
Issuer symbol
BPMC
Transactions as of
15 Mar 2023
Net transactions value
-$375,197
Form type
4
Filing time
19 Mar 2024, 16:48:44 UTC
Previous filing
08 Mar 2023
Next filing
19 Dec 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BPMC Common Stock Options Exercise $12,008 +800 +4.5% $15.01 18,662 15 Mar 2024 Direct F1
transaction BPMC Common Stock Sale $69,824 -800 -4.3% $87.28 17,862 15 Mar 2024 Direct F1
transaction BPMC Common Stock Options Exercise $12,008 +800 +4.5% $15.01 18,662 15 Mar 2024 Direct F1
transaction BPMC Common Stock Sale $72,000 -800 -4.3% $90.00 17,862 15 Mar 2024 Direct F1
transaction BPMC Common Stock Sale $257,389 -2,949 -17% $87.28 14,913 15 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BPMC Stock Option (Right to Buy) Options Exercise $0 -1,600 -50% $0.000000 1,600 15 Mar 2024 Common Stock 1,600 $15.01 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Effected pursuant to a trading plan adopted on September 13, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 This option was granted on February 3, 2016 and is fully vested as of the date hereof.